Ignite Creation Date:
2024-05-05 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00471094
Status:
COMPLETED
Last Update Posted:
2012-02-02
First Post:
2007-05-07
Brief Title:
Safety and Efficacy of Ilaprazole 5 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis
Sponsor:
Takeda
Organization:
Takeda
Study Overview
Official Title:
A Phase 2 Study to Evaluate the Safety and Efficacy of Ilaprazole 5 mg QD 20 mg QD and 40 mg QD and an Active Comparator Lansoprazole 30 mg QD on Healing of Erosive Esophagitis
Status:
COMPLETED
Status Verified Date:
2012-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the efficacy and safety of 8 weeks of daily treatment with Ilaprazole 5 20 and 40 mg once daily QD compared to lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis
Detailed Description:
This 8 week study will be conducted by approximately 160 investigators in the United States During this study esophagitis healing will be evaluated by endoscopy heartburn and other symptom relief will be evaluated by questionnaire and study drug levels will be measured
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U1111-1127-6202 | REGISTRY | WHO | None |